Sanofi: Breast Neoplasms trials
The registry lists 40 Breast Neoplasms studies with Sanofi as lead sponsor. 0 are open to participants now and 14 have results posted.
Phase 1 7Phase 2 25Phase 3 11No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related ToxicityTerminatedNCT05128773Phase 3Results posted
- Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid TumorsTerminatedNCT04659603Phase 2Results posted
- Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast CancerTerminatedNCT04478266Phase 3Results posted
- Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast CancerTerminatedNCT04191382Phase 2Results posted
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerTerminatedNCT04059484Phase 2Results posted
- Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerTerminatedNCT03284957Phase 1/2Results posted
- ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex TrialTerminatedNCT00752986Phase 2Results posted
- Docetaxel in Node Positive Adjuvant Breast CancerCompletedNCT00688740Phase 3Results posted
- E3 Breast Cancer Taxotere CombinationCompletedNCT00494481Phase 2Results posted
- Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast CancerCompletedNCT00446030Phase 2Results posted
- Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast CancerCompletedNCT00365365Phase 2Results posted
- Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast CancerCompletedNCT00364611Phase 2Results posted
- Docetaxel in Breast CancerCompletedNCT00312208Phase 3Results posted
- Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast CancerCompletedNCT00021255Phase 3Results posted
- Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid TumorsTerminatedNCT05013554Phase 1
- Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal WomenCompletedNCT04940026Phase 1
- Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)TerminatedNCT03816839Phase 1
- Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast CancerCompletedNCT02664103Phase 2
- Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer PatientsCompletedNCT01204125Phase 2
- A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain MetastasisCompletedNCT01173497Phase 2
- An Open-Label, Expanded Access Protocol of Iniparib Breast CancerNo longer availableNCT01130259
- Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast CancerCompletedNCT01082068Phase 1/2
- Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast CancerCompletedNCT01045304Phase 2
- Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based RegimenCompletedNCT01042925Phase 1/2
- A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast CancerCompletedNCT00938652Phase 3
- Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)CompletedNCT00917748Phase 3
- Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast CancerTerminatedNCT00774878Phase 2
- To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single AgentTerminatedNCT00620100Phase 2
- GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast CancerCompletedNCT00617968Phase 2
- A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast CancerCompletedNCT00540358Phase 2
- Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer PatientsCompletedNCT00485979Phase 2
- Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast CancerCompletedNCT00387907Phase 2
- XRP9881 in Combination With Trastuzumab in Metastatic Breast CancerCompletedNCT00386685Phase 2
- Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast CancerCompletedNCT00327743Phase 1/2
- Study of Docetaxel in Breast Cancer PatientsCompletedNCT00174707Phase 3
- BIG 02/98 Docetaxel - Breast CancerCompletedNCT00174655Phase 3
- Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine TreatmentCompletedNCT00087958Phase 2
- Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast CancerCompletedNCT00081796Phase 3
- This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast CancerCompletedNCT00034918Phase 2
- Paclitaxel or Docetaxel in Treating Women With Advanced Breast CancerCompletedNCT00002662Phase 3